Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) enjoyed a 194.95% run-up in share price since hitting record low of $0.99. The stock managed 22.18% rise and now stands at $2.92 as of 11/20/2017. At recent session, the prices were hovering between $2 and $3.15. This company shares are 2.74% off its target price of $3 and the current market capitalization stands at $74.5M. The recent change has given its price a 132.98% lead over SMA 50 and -40.41% deficit over its 52-week high. The stock witnessed 158.41% gains, 108.57% gains and 114.71% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found EKSO’s volatility during a week at 25.16% and during a month it has been found around 13.5%.Ekso Bionics Holdings, Inc. (EKSO) Top Holders
Institutional investors currently hold around $9 million or 94.4% in EKSO stock. Look at its top three institutional owners. Vanguard Group Inc owns $2.71 million in Ekso Bionics Holdings, Inc., which represents roughly 3.64% of the company’s market cap and approximately 30.14% of the institutional ownership. Similar statistics are true for the second largest owner, Sabby Management, Llc, which owns 702,364 shares of the stock are valued at $1.68 million. The third largest holder is National Planning Corp, which currently holds $1.25 million worth of this stock and that ownership represents nearly 1.67% of its market capitalization.Ekso Bionics Holdings, Inc. 13F Filings
At the end of 09/30/2017 reporting period, 24 institutional holders increased their position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by some 2,334,389 shares, 13 decreased positions by 51,597 and 8 held positions by 1,435,456. That puts total institutional holdings at 3,821,442 shares, according to SEC filings. The stock grabbed 8 new institutional investments totaling 1,195,109 shares while 3 institutional investors sold out their entire positions totaling 19,701 shares.Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Insider Trades
Multiple company employees have indulged in significant insider trading. Ekso Bionics Holdings, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Peurach Jack has acquired 20,000 shares of Ekso Bionics Holdings, Inc. (EKSO) in trading session dated Sep. 14, 2017. These shares are worth $25,400 and were traded at $1.27 each. The SEC filing shows that Wendell Amy Mcbride performed a purchase of 16,264 shares. The Director added these shares by way of transaction on Sep. 14, 2017. The company’s shares were assimilated at $1.23 per share worth to an investment of some $20,005 on account of Wendell Amy Mcbride.
President & CEO, Looby Thomas, purchased 15,000 common shares of Ekso Bionics Holdings, Inc. (EKSO) in the open market. In a transaction dated Sep. 08, 2017, the shares were bought at an average price of $1.13, giving away a sum of $16,950. After this purchase, 20,315 common shares of EKSO are directly owned by the insider, with total stake valued at $59,320.
In the transaction dated Sep. 07, 2017, the great number of shares acquired came courtesy the CFO; Scheder-Bieschin Max added a total of 10,000 shares at an average price of $1.13, amounting to approximately $11,300. The insider now directly owns 32,371 shares worth $94,523.Ekso Bionics Holdings, Inc. (EKSO) Analyst Guide
Not many analysts have released their opinion on Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.